Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Italy Revenue	316.33M	329.19M	336.26M
International Revenue	2.39B	2.29B	2.01B
Revenue (Total)	2.71B	2.62B	2.34B

Revenue by Geography 2

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Europe Revenue	-	1.74B	1.65B
Asia and Oceania Revenue	-	204.76M	156.01M
America Revenue	-	605.34M	477.46M
Africa Revenue	-	72.42M	58.03M
Revenue (Total)	2.71B	2.62B	2.34B

Revenue Breakdown

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Specialty & Primary Care Revenue	1.50B	1.54B	1.51B
Rare Diseases Revenue	1.17B	1.08B	833.86M
Revenue (Other)	33.34M	-	-
Revenue (Total)	2.71B	2.62B	2.34B

Revenue Breakdown 2

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Cardiovascular Revenue	396.00M	396.02M	385.21M
Urology and Uro-Oncology Revenue	412.14M	410.05M	399.94M
Gastrointestinal Revenue	250.92M	238.94M	217.50M
Cough and Cold Revenue	118.55M	124.30M	137.28M
Other Treatment Areas Revenue	299.35M	308.58M	309.31M
Pharmaceutical Chemicals Revenue	58.73M	59.05M	58.47M
Hema-Oncology Revenue	444.58M	414.86M	253.23M
Endocrinology Revenue	463.50M	394.08M	321.69M
Metabolic and Other Areas Revenue	261.56M	272.51M	258.94M
Revenue (Total)	2.71B	2.62B	2.34B

Revenue Breakdown 3

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Pharmaceutical Chemicals Revenue	58.73M	59.05M	58.47M
Revenue (Total)	2.71B	2.62B	2.34B

EBITDA

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Specialty & Primary Care EBITDA	525.39M	526.50M	524.44M
Rare Diseases EBITDA	509.51M	464.56M	341.33M
Operating Income (Other)	-275.92M	-320.25M	-226.91M
Operating Income (Total)	758.98M	670.81M	638.86M

EBIT

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Specialty & Primary Care Operating Income	399.08M	394.82M	426.73M
Rare Diseases Operating Income	359.90M	275.99M	212.13M
Operating Income (Total)	758.98M	670.81M	638.86M

Key Performance Indicators

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Specialty & Primary Care Like-For-Like Growth	3.80%	5.70%
Rare Diseases Like-For-Like Growth	16.60%	15.70%
Total Like-For-Like Growth	8.30%	9.20%

Data Source: Fiscal.ai Last updated: Jul 28, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 14, 2026

Data Sources Report a data error